Keyphrases
Acquired Resistance
7%
Activating mutation
6%
Adenocarcinoma
7%
Adverse Events
10%
Afatinib
6%
Breast Cancer Susceptibility Gene 1 (BRCA1)
17%
Chemotherapy
35%
Cisplatin
17%
Clinical Practice Guidelines
8%
Confidence Interval
10%
Docetaxel
15%
Durvalumab
6%
EGFR mutation
68%
Epidermal Growth Factor Receptor
35%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
29%
Erlotinib
35%
Exon 19
6%
Gefitinib
14%
Gemcitabine
7%
Hazard Ratio
8%
Immune Checkpoint Inhibitors
6%
Immunohistochemistry
6%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
33%
Lung Adenocarcinoma
19%
Lung Cancer
54%
Lung Cancer Patients
14%
Median Survival
8%
Monotherapy
7%
MRNA Expression
14%
MRNA Level
6%
Nivolumab
7%
Non-small Cell Lung Cancer (NSCLC)
70%
Non-small Cell Lung Cancer Patients
40%
Osimertinib
8%
Overall Survival
16%
Phase II Study
8%
Phase II Trial
11%
Programmed Death-ligand 1 (PD-L1)
9%
Progression-free Survival
25%
Randomized Phase II Trial
7%
Response Prediction
6%
Small Cell Lung Cancer
14%
Solid Tumors
7%
Spain
7%
Stage III Non-small Cell Lung Cancer
8%
Stage IV Non-small Cell Lung Cancer
10%
T790M mutation
7%
Targeted Therapy
11%
Tumor
12%
Tyrosine Kinase Inhibitor
7%
Pharmacology, Toxicology and Pharmaceutical Science
Adenocarcinoma
5%
Adverse Event
15%
Afatinib
6%
Anticarcinogen
6%
Biological Marker
9%
Breast Cancer
6%
Chemoradiation Therapy
6%
Chemotherapy
43%
Cisplatin
23%
Clinical Trial
8%
Disease
20%
Docetaxel
14%
Durvalumab
6%
Epidermal Growth Factor Receptor
81%
Epidermal Growth Factor Receptor Kinase Inhibitor
19%
Erlotinib
29%
Gefitinib
9%
Gemcitabine
6%
Immune Checkpoint Inhibitor
5%
Immunotherapy
13%
Lung Adenocarcinoma
14%
Lung Cancer
67%
Malignant Neoplasm
19%
Messenger RNA
17%
Monotherapy
6%
Neoplasm
21%
Nivolumab
7%
Non Small Cell Lung Cancer
100%
Osimertinib
9%
Overall Survival
21%
Progression Free Survival
28%
Protein Tyrosine Kinase
5%
Protein Tyrosine Kinase Inhibitor
10%
Receptor
6%
SARS Coronavirus
5%
Small Cell Lung Cancer
13%
Solid Malignant Neoplasm
11%
Medicine and Dentistry
Adverse Event
8%
Biological Marker
6%
Breast Cancer
8%
Chemotherapy
30%
Cisplatin
12%
Clinical Guideline
8%
Diseases
10%
Docetaxel
5%
Durvalumab
6%
Epidermal Growth Factor Receptor
59%
Epidermal Growth Factor Receptor Kinase Inhibitor
15%
Erlotinib
9%
Exon
7%
Ganglioglioma
5%
Gefitinib
5%
Hazard Ratio
5%
Human Immunodeficiency Virus
5%
Immune Checkpoint Inhibitor
6%
Immunotherapy
15%
Lung Adenocarcinoma
9%
Lung Cancer
49%
Malignant Neoplasm
10%
Messenger RNA
9%
Neoplasm
18%
Nivolumab
7%
Non Small Cell Lung Cancer
68%
Non-Small Cell Lung Cancer
6%
Oncology
7%
Overall Survival
13%
Primary Tumor
5%
Programmed Cell Death
6%
Programmed Death-Ligand 1
7%
Progression Free Survival
11%
Protein Tyrosine Kinase
5%
Radiation Therapy
5%
Small Cell Lung Cancer
18%
Solid Malignant Neoplasm
6%
Targeted Therapy
7%
Tyrosine-Kinase Inhibitor
5%